F. Jeanjean, G. Fournet, D. Le Bars, J. Gore
FULL PAPER
Preparation of N-(α-Stannylalkyl)oxazolidinones
4.86 (d, J ϭ 8.4 Hz, 1 H), 5.77 (d, J ϭ 8.4 Hz, 1 H), 6.9–7.03 (m,
10 H). – 13C NMR (CDCl3, 50 MHz): δ ϭ 10.3 (CH2, Bu3Sn), 13.4
(CH2, Bu3Sn), 14.6 (CH3), 27.2 (CH2, Bu3Sn), 28.8 (CH2, Bu3Sn),
31.2 (CH2) 32.2 (CH2), 44.3 (CH), 67.9 (CH), 78.9 (CH), 125.5
(CH), 127.3 (CH), 127.5 (CH), 127.8 (CH), 128.2 (CH), 128.3
(CH), 134.8 (C), 135.0 (C), 158.2 (C), 170.6 (C).
(4S,1ЈR)-3-[3-(Methylthio)-1-(tributylstannyl)propyl]-4-phenyloxa-
zolidin-2-one (1aaα) and (4S,1ЈS)-3-[3-(Methylthio)-1-(tributylstan-
nyl)propyl]-4-phenyloxazolidin-2-one (1aaβ): Sodium hydride
(72 mg, 60% dispersion in oil, 1.8 mmol) was added at room temp.
to a solution of (S)-4-phenyloxazolidin-2-one (0.24 g, 1.47 mmol)
in DMF (6 mL). The mixture was stirred for 30 min before adding
a solution of bromostannane 4a (0.825 g, 1.8 mmol) in DMF
(1.2 mL). After 4 h, water was carefully added to the mixture and
the solution was extracted with AcOEt (3 ϫ 25 mL). The combined
organic phases were washed with brine (3 ϫ 30 mL), dried over
Na2SO4 and concentrated under reduced pressure. The residue was
purified by FC (petroleum ether/AcOEt ϭ 90:10 then 80:20), a 1:1
mixture of diastereomers 1aaα/1aaβ was obtained as a colourless
oil (0.715 g, 90%). The two diastereomers were separated by FC
(petroleum ether/AcOEt ϭ 95:5).
(4S,1ЈR)-3-[3-Methyl-1-(tributylstannyl)butan-1-yl]-4-phenyloxa-
zolidin-2-one (1bα) and (4S,1ЈS)-3-[3-methyl-1-(tributylstannyl)bu-
tan-1-yl]-4-phenyloxazolidin-2-one (1bβ): Prepared as described for
1aa by alkylation of the sodium salt of (S)-4-phenyloxazolidium-2-
one with the bromostannane 4b (7.4 mmol). FC purification (petro-
leum ether/AcOEt 90:10) gave a 1:1 mixture of diastereomers 4bα
and 4bβ as a viscous oil, yield 84%. The two diastereomers are
separated by FC (petroleum ether ϭ 95/5).
1bα: [α]D ϭ ϩ23.05 (c ϭ 1.2, CHCl3). – IR (α ϩ β, film): ν˜ ϭ 3080,
3060, 3020, 1745 cm–1. – 1H NMR (CDCl3, 300 MHz): δ ϭ 0.78
(d, J ϭ 6.25 Hz, 3 H), 0.82–0.92 (m, 15 H), 1.22–1.50 (m, 16 H),
1.64–1.72 (m, 2 H), 2.71 (t, J ϭ 7.5 Hz, 1 H), 4.10 (dd, J ϭ 7.72,
JAB ϭ 8.8 Hz, 1 H), 4.59 (apparent t, J ϭ 9 Hz, 1 H), 4.83
(apparent t, J ϭ 8.3 Hz, 1 H), 7.26–7.42 (m, 5 H). – 13C NMR
(CDCl3, 75 MHz): δ ϭ 10.6 (CH2, Bu3Sn), 13.7 (CH3, Bu3Sn), 22.5
(CH3), 22.7 (CH3), 26.6 (CH), 27.5 (CH2, Bu3Sn) 29.1 (CH2,
Bu3Sn), 39.4 (CH), 40.8 (CH), 62.2 (CH), 69.4 (CH2), 127.4 (CH),
129.1 (CH), 129.2 (CH), 138.3 (C), 158.6 (C). – C26H45NO2Sn
(522.35): calcd. C 59.79, H 8.68; found C 60.00, H 8.93.
1aaα: [α]D ϭ ϩ22.9 (c ϭ 2.2, CHCl3). – IR (film): ν˜ ϭ 3080, 3060,
3040, 1740, 1605, 1590, 760, 700 cm–1. – 1H NMR (CDCl3,
300 MHz): δ ϭ 0.75–0.95 (m, 15 H), 1.15–1.50 (m, 12 H) 2.10 (s,
3 H), 1.85–2.15 (m, 2 H), 2.45 (t, J ϭ 7.0 Hz, 2 H) 2.75 (dd, J ϭ
5.99 Hz, J ϭ 6.61 Hz, 1 H), 4.15 (dd, J ϭ 7.35 Hz, J ϭ 8.82 Hz, 1
H), 4.60 (t, J ϭ 8.82 Hz, 1 H), 4.86 (dd, J ϭ 7.35 Hz, J ϭ 8.82 Hz,
1 H), 7.30–7.45 (m, 5 H). – 13C NMR (CDCl3, 50 MHz): δ ϭ 10.9
(CH2, Bu3Sn),13.7 (CH3, Bu3Sn), 27.4 (CH2, Bu3Sn), 29.0 (CH2,
Bu3Sn), 30.9 (CH2), 32.7 (CH2), 40.1 (CH), 61.5 (CH), 69.3 (CH2),
127.4 (CH2), 129.1 (CH2), 138.0 (C), 158.7 (C). – C25H43NO2SSn
(540.4): calcd. C 55.57, H 8.02; found C 55.96, H 8.16.
1bβ: Eluting first. – [α]D ϭ ϩ23.9 (c ϭ 2.4, CHCl3). – 1H NMR
(CDCl3, 300 MHz): δ ϭ 0.54 (d, J ϭ 6.6 Hz, 3 H), 0.58 (d, J ϭ
6.6 Hz, 1 H), 0.83–0.93 (m, 15 H), 1.24–1.50 (m, 13 H), 1.62–1.78
(m, 2 H), 2.84 (dd, J ϭ 6.98 Hz, J ϭ 9.19 Hz, 1 H), 4.21 (m, 1 H),
4.48–4.60 (m, 2 H), 7.34–7.40 (m, 5 H). – 13C NMR (CDCl3,
75 MHz): δ ϭ 10.2 (CH2, Bu3Sn), 13.7 (CH3, Bu3Sn), 21.9 (CH3),
22.6 (CH3), 25.8 (CH), 27.5 (CH2, Bu3Sn), 29.2 (CH2, Bu3Sn), 41.6
(CH2), 42.6 (CH), 63.2 (CH), 69.5 (CH2), 128.1 (CH), 129.1 (CH),
129.3 (CH), 138.4 (C), 158.4 (C). – C26H45NO2Sn (522.35): calcd.
C 59.79, H 8.68; found C 59.61, H 8.53.
1aaβ: Eluting first. – [α]D ϭ ϩ21.5 (c ϭ 2.3, CHCl3). – IR (film):
ν˜ ϭ 3080, 3060, 3040, 1740, 1605, 1590, 760, 700 cm–1. – 1H NMR
(CDCl3, 300 MHz): δ ϭ 0.80–0.95 (m, 15 H) 1.20–1.55 (m, 12 H),
1.79 (s, 3 H), 1.85–1.95 (m, 2 H), 2.10–2.20 (m, 2 H), 2.92 (apparent
t, J ϭ 7.6 Hz, 1 H), 4.24 (dd, J ϭ 5.52 Hz, J ϭ 6.61 Hz, 1 H),
4.48–4.62 (m, 2 H), 7.41 (m, 5 H). – 13C NMR (CDCl3, 50 MHz):
δ ϭ 10.4 (CH2, Bu3Sn), 13.6 (CH3, Bu3Sn), 14.8 (CH3), 27.4 (CH2,
Bu3Sn), 29.1 (CH2, Bu3Sn), 31.4 (CH2), 32.4 (CH2), 43.7 (CH) 63.4
(CH), 69.5 (CH2), 127.9 (CH), 129.1 (CH), 129.3 (CH), 138.4 (C),
158.6 (C). – C25H43NO2SSn (540.4): calcd. C 55.57, H 8.02; found
C 55.62, H 8.05.
(4S,1ЈR)-3-[1-(Tributylstannyl)ethyl]-4-phenyloxazolidin-2-one (1cα)
and (4S,1ЈS)-3-[1-(Tributylstannyl)ethyl]-4-phenyloxazolidin-2-one
(1cβ) Prepared as described for 1aa by alkylation of the sodium
salt of (S)-4-phenyloxazolidin-2-one with the bromostannane 4c.
Ϫ Scale 5.2 mmol. Ϫ A FC purification (petroleum ether/AcOEt ϭ
90/10) gave a 1/1 mixture of diastereomers 1cα and 1cβ as a viscous
oil, yield 71%. The two diastereomers were separated by FC (petro-
leum ether/ACOEt ϭ 95/5).
(4S,5R,1ЈR)-3-[3-(Methylthio)-1-(tributylstannyl)propyl]-4,5-di-
phenyloxazolidin-2-one (1abα) and (4S,5R,1ЈS)-3-[3-(Methylthio)-1-
(tributylstannyl)propyl]-4,5-diphenyloxazolidin-2-one (1abβ): Pre-
pared as described for 1aaα by alkylation of the sodium salt of
(4S,5R)-4,5-diphenyloxazolidin-2-one with the bromostannane 4a
(2.8 mmol). FC purification (petroleum ether/AcOEt 90:10) gave a
1:1 mixture of diastereomers 1abα and 1abβ as a viscous oil, yield
87%. Ϫ IR (α ϩ β, film): ν˜ ϭ 3060, 3020, 1735 cm–1. The two
diastereomers were separated by FC (petroleum ether/AcOEt ϭ
95:5).
˜
1cα: [α]D ϭ ϩ39.7 (c ϭ 1.35, CHCl3). Ϫ IR (α ϩ β, film): ν ϭ
1
3065, 3025, 1740 cm–1. – H NMR (CDCl3, 300 MHz): δ ϭ 0.84–
0.92 (m, 15 H), 1.18–1.31 (m, 9 H), 1.40–1.50 (m, 6 H), 2.58 (q,
J ϭ 7.3 Hz, 1 H), 4.05 (apparent t, JAB ϭ 8.1 Hz, 1 H), 4.57 (t,
J ϭ 8.8 Hz, 1 H), 4.93 (apparent t, JAB ϭ 8.1 Hz, 1 H), 7.26–7.44
(m, 5 H). – 13C NMR (CDCl3, 75 MHz): δ ϭ 10.7 (CH2, Bu3Sn),
13.8 (CH3, Bu3Sn), 15.9 (CH3), 27.5 (CH2, Bu3Sn), 29.2 (CH2,
Bu3Sn), 35.2 (CH), 59.8 (CH), 69.4 (CH2), 127.2 (CH), 129.0 (CH),
129.2 (CH), 138.1 (C), 158.9 (C). – C23H39NO2Sn (480.27): calcd.
C 5.52 H 8.18; found C 57.54, H 8.38.
1abα: [α]D ϭ ϩ18.3 (c ϭ 1.2, CHCl3). – 1H NMR (CDCl3,
200 MHz): δ ϭ 0.75 –1.00 (m, 15 H), 1.20–1.60 (m, 12 H), 1.95–
2.10 (m, 2 H), 2.10 (s, 3 H), 2.45–2.60 (m, 2 H), 2.79 (t, J ϭ
6.25 Hz, 1 H), 5.22 (d, J ϭ 8.6 Hz, 1 H), 5.81 (d, J ϭ 8.6 Hz, 1 H),
6.81–7.12 (m, 10 H). – 13C NMR (CDCl3, 50 MHz): δ ϭ 11.3
(CH2, Bu3Sn), 13.7 (CH3, Bu3Sn), 15.6 (CH3), 27.5 (CH2, Bu3Sn),
29.1 (CH2, Bu3Sn), 31.3 (CH2), 32.8 (CH2), 41.1 (CH2), 66.3 (CH),
78.8 (CH), 125.9 (CH), 127.7 (CH), 127.8 (CH), 128.2 (CH, ϫ2),
128.3 (CH), 134.1 (C), 135.1 (C), 159.2 (C).
1cβ: Eluting first – [α]D ϭ ϩ24 (c ϭ 1.9, CHCl3). – 1H NMR
(CDCl3, 300 MHz): δ ϭ 0.84–0.94 (m, 15 H) 1.16 (d, J ϭ 7.4 Hz,
3 H), 1.26–1.55 (m, 12 H), 2.78 (m, 1 H), 4.14 (dd, J ϭ 5.9 Hz,
J ϭ 7.35 Hz, 1 H), 4.51–4.62 (m, 2 H), 7.31–7.47 (m, 5 H). – 13C
1
1abβ: Eluting first. – [α]D ϭ ϩ18.3 (c ϭ 1.2, CHCl3). – H NMR
(CDCl3, 200 MHz): δ ϭ 0.80–1.00 (m, 15 H), 1.15–1.60 (m, 12 H), NMR (CDCl3, 75 MHz): δ ϭ 10.2 (CH2, Bu3Sn), 13.7 (CH3,
1.75 (s, 3 H), 1.90–2.25 (m, 4 H), 3.1 (dd, J ϭ 6.8, 7.6 Hz, 1 H), Bu3Sn), 18.8 (CH3), 27.5 (CH2, Bu3Sn), 29.2 (CH2, Bu3Sn), 39.2
1302
Eur. J. Org. Chem. 2000, 1297Ϫ1305